Another promising group of antidiabetic drugs, the dual glucagon-like peptide and glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonists, have shown neuroprotective effects in animal models of AD (Holscher, 2018; Zhang and Holscher, 2020). This evidence concerns the gene GLP1R and Alzheimer disease.